Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis

Differential Treatment Outcomes in BRCA1/2 ‐, CDK12 ‐, and ATM ‐Mutated Metastatic Castration‐Resistant Prostate Cancer

(2021) Daniel H. Kwon et al.   CANCER

Real-world outcomes among prostate cancer patients with BRCA2 gene variants compared to variants in other homologous DNA repair genes.

(2021) Meghan Price et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study

(2021) Baijun Dong et al.   Journal of the National Comprehensive Cancer Network

Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions

(2021) Rodney J. Scott et al.   Oncotarget

Targeting resistant prostate cancer with ATR and PARP inhibition (TRAP trial): A phase II study.

(2020) Zachery R. Reichert et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib for Metastatic Castration-Resistant Prostate Cancer

(2020) Johann de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

(2020) Rebecca L. Lloyd et al.   ONCOGENE

High-throughput functional evaluation of BRCA2 variants of unknown significance

(2020) Masachika Ikegami et al.   Nature Communications

Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays

(2020) Peter Bouwman et al.   CLINICAL CANCER RESEARCH

Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients

(2020) Junlong Wu et al.   INTERNATIONAL JOURNAL OF CANCER

Comparative analysis of genomic alterations across castration-sensitive and castration-resistant prostate cancer via circulating tumor DNA sequencing

(2020) Liancheng Fan et al.   JOURNAL OF UROLOGY

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

(2020) Maha Hussain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer

(2020) Albert Jang et al.   Cancers

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer

(2019) Elena Castro et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations

(2019) Catherine H. Marshall et al.   EUROPEAN UROLOGY

PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers

(2019) Patrick G. Pilié et al.   CLINICAL CANCER RESEARCH

Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients

(2019) Yu Wei et al.   EUROPEAN UROLOGY

Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study

(2019) Tommy Nyberg et al.   EUROPEAN UROLOGY

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

(2019) Elizabeth C. Page et al.   EUROPEAN UROLOGY

Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review

(2019) Stephanie L Swift et al.   Future Oncology

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

(2019) Lisanne F. van Dessel et al.   Nature Communications

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

(2019) Joaquin Mateo et al.   LANCET ONCOLOGY

The functional impact of variants of uncertain significance in BRCA2

(2018) Romy L. S. Mesman et al.   GENETICS IN MEDICINE

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population

(2018) Gyorgy Petrovics et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer

(2017) Matti Annala et al.   EUROPEAN UROLOGY

DNA Repair in Prostate Cancer: Biology and Clinical Implications

(2017) Joaquin Mateo et al.   EUROPEAN UROLOGY

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

(2017) Marilyn M. Li et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

(2016) Colin C. Pritchard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

(2015) Sue Richards et al.   GENETICS IN MEDICINE

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

GermlineBRCAMutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer

(2013) Elena Castro et al.   JOURNAL OF CLINICAL ONCOLOGY

BRCA1/2 Sequence Variants of Uncertain Significance: A Primer for Providers to Assist in Discussions and in Medical Management

(2013) N. M. Lindor et al.   ONCOLOGIST

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients

(2011) Z Kote-Jarai et al.   BRITISH JOURNAL OF CANCER